One of Glax­o­SmithK­line's top can­cer drug prospects goes down in 3rd straight set­back, leav­ing a $4B deal on life sup­port

One of Hal Bar­ron’s big-tick­et part­ner­ships has tak­en an­oth­er bad hit, fail­ing the third straight study in a se­ries of can­cer stud­ies and look­ing com­plete­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER